Pamicogrel
CAS No. 101001-34-7
Pamicogrel( KBT3022 )
Catalog No. M22618 CAS No. 101001-34-7
Pamicogrel is an inhibitor of COX. Pamicogrel has platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 31 | In Stock |
|
5MG | 50 | In Stock |
|
10MG | 80 | In Stock |
|
25MG | 149 | In Stock |
|
50MG | 258 | In Stock |
|
100MG | 417 | In Stock |
|
200MG | 601 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePamicogrel
-
NoteResearch use only, not for human use.
-
Brief DescriptionPamicogrel is an inhibitor of COX. Pamicogrel has platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion.
-
DescriptionPamicogrel is an inhibitor of COX. Pamicogrel has platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion. Pamicogrel also has potential in both prophylaxis and treatment of ischemic brain injury.
-
In VitroPamicogrel is a cyclooxygenase inhibitor with platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion. Pamicogrel also has potential in both prophylaxis and treatment of ischemic brain injury.
-
In Vivo——
-
SynonymsKBT3022
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number101001-34-7
-
Formula Weight448.53
-
Molecular FormulaC25H24N2O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO:82 mg/mL (182.82 mM; Need ultrasonic)
-
SMILESCCOC(=O)Cn1cccc1-c1nc(c(s1)-c1ccc(OC)cc1)-c1ccc(OC)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Light P. Pamicogrel (Kanebo). IDrugs. 1999 Sep;2(9):938-42.
molnova catalog
related products
-
Emodin-8-glucoside
Emodin-8-beta-D-glucoside functions to protect from focal cerebral injury induced by ischemia and reperfusion.
-
Gaultherin
Gaultherin has analgesic, and anti-inflammatory activities.Gaultherin lacks gastric ulcerogenic effect, because of it released salicylate in intestine slowly, not in stomach and it left the cyclooxygenase-1 unaffected, which was the source of cytoprotective prostaglandins in gastric epithelium.
-
Polmacoxib
Polmacoxib (CG-100649) is a novel NSAID proposed to inhibit both COX-2 and carbonic anhydrase (CA)-I/-II.